Menu

Stem Cells Not Rejected

Researchers uncover more evidence that reprogrammed stem cells are not attacked by the immune system, suggesting they may one day serve as effective therapies.

Jan 25, 2013
Dan Cossins

WIKIMEDIA, NISSIM BENVENISTYResearchers have coaxed induced pluripotent stem cells (iPSCs) derived from mice to become several different cell lines and transplanted those cells into genetically identical mice without triggering a strong immune response.

The study, published this week (January 24) in Cell Stem Cell, comes hot on the heels of similar findings reported earlier this month, strengthening the case that cells generated from iPSCs could eventually be used for cell replacement therapy to treat various human diseases.

Because iPSCs can be derived from a patient’s own tissues, researchers believed that transplantation into that patient should not provoke an immune response. But in 2011, Yang Xu’s team at the University of California, Sand Diego, called such assumptions into question when they provided evidence that iPSCs derived from mice were attacked and rejected by the immune system when implanted into genetically identical mice.

This prompted Ashleigh Boyd and colleagues at Boston University Medical School to try a similar experiment themselves. They differentiated mouse-derived iPSCs into three different cell lines with two different methods and assessed the immune response, both in vitro and after transplantation into genetically identical mice. They found no evidence that white blood cell count increased in vitro, nor of immune rejection in the transplant experiments.

The researchers concede that the discrepancy between their results and Xu’s findings may result from transplanting the cells into different parts of the body. Nevertheless, they wrote, “our data support the idea that differentiated cells generated from autologous iPSCs could be applied for cell replacement therapy without eliciting immune rejection.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!